Is AKTS or EWTX more profitable?

Aktis Oncology's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Edgewise Therapeutics N/A -39.01% -36.96%

Does the media refer more to AKTS or EWTX?

In the previous week, Edgewise Therapeutics had 9 more articles in the media than Aktis Oncology. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.56 beat Edgewise Therapeutics' score of 0.52 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AKTS or ACAD?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 4 mentions for Aktis Oncology. ACADIA Pharmaceuticals' average media sentiment score of 0.69 beat Aktis Oncology's score of 0.56 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AKTS or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 163.07 -$63.73M -$0.82 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is AKTS or PBLS more profitable?

Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Parabilis Medicines N/A N/A N/A

Does the media favor AKTS or PBLS?

In the previous week, Parabilis Medicines had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for Parabilis Medicines and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.56 beat Parabilis Medicines' score of 0.34 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AKTS or IOVA?

In the previous week, Iovance Biotherapeutics had 9 more articles in the media than Aktis Oncology. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 4 mentions for Aktis Oncology. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Aktis Oncology's score of 0.56 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Aktis Oncology N/A N/A N/A

Does the media prefer RLAY or AKTS?

In the previous week, Aktis Oncology had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.65 beat Aktis Oncology's score of 0.56 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aktis Oncology (AKTS) Competitors

$19.72 -2.39 (-10.81%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$19.70 -0.02 (-0.13%)

As of 09/23/2026 07:30 PM Eastern

Compare

AKTS vs. EWTX, ACAD, PBLS, IOVA, and RLAY

Should you buy Aktis Oncology stock or one of its competitors? Aktis Oncology's main competitors and comparable companies include Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), Parabilis Medicines (PBLS), Iovance Biotherapeutics (IOVA), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aktis Oncology compare to Edgewise Therapeutics?

Aktis Oncology (NASDAQ:AKTS) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

28.8% of Aktis Oncology shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aktis Oncology currently has a consensus price target of $35.63, suggesting a potential upside of 80.65%. Edgewise Therapeutics has a consensus price target of $51.33, suggesting a potential upside of 25.05%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Edgewise Therapeutics had 9 more articles in the media than Aktis Oncology. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.56 beat Edgewise Therapeutics' score of 0.52 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has higher revenue and earnings than Edgewise Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	163.07	-$63.73M	-$0.82	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Aktis Oncology's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Summary

Aktis Oncology beats Edgewise Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Aktis Oncology (NASDAQ:AKTS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for ACADIA Pharmaceuticals and 4 mentions for Aktis Oncology. ACADIA Pharmaceuticals' average media sentiment score of 0.69 beat Aktis Oncology's score of 0.56 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	163.07	-$63.73M	-$0.82	N/A
ACADIA Pharmaceuticals	$1.07B	4.09	$391M	$2.22	11.45

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Aktis Oncology's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Aktis Oncology currently has a consensus target price of $35.63, suggesting a potential upside of 80.65%. ACADIA Pharmaceuticals has a consensus target price of $34.36, suggesting a potential upside of 35.12%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Aktis Oncology on 12 of the 16 factors compared between the two stocks.

How does Aktis Oncology compare to Parabilis Medicines?

Aktis Oncology (NASDAQ:AKTS) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Parabilis Medicines had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 5 mentions for Parabilis Medicines and 4 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.56 beat Parabilis Medicines' score of 0.34 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aktis Oncology presently has a consensus price target of $35.63, suggesting a potential upside of 80.65%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 25.09%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Parabilis Medicines	N/A	N/A	N/A

28.8% of Aktis Oncology shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Parabilis Medicines has lower revenue, but higher earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	163.07	-$63.73M	-$0.82	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Summary

Aktis Oncology beats Parabilis Medicines on 7 of the 8 factors compared between the two stocks.

How does Aktis Oncology compare to Iovance Biotherapeutics?

Aktis Oncology (NASDAQ:AKTS) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aktis Oncology has higher earnings, but lower revenue than Iovance Biotherapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	163.07	-$63.73M	-$0.82	N/A
Iovance Biotherapeutics	$263.50M	17.52	-$390.98M	-$0.73	N/A

Aktis Oncology currently has a consensus price target of $35.63, suggesting a potential upside of 80.65%. Iovance Biotherapeutics has a consensus price target of $9.11, suggesting a potential downside of 10.59%. Given Aktis Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aktis Oncology is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Iovance Biotherapeutics had 9 more articles in the media than Aktis Oncology. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 4 mentions for Aktis Oncology. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Aktis Oncology's score of 0.56 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Aktis Oncology's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Summary

Aktis Oncology beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Aktis Oncology compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Aktis Oncology had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.65 beat Aktis Oncology's score of 0.56 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Relay Therapeutics currently has a consensus price target of $25.92, indicating a potential upside of 43.74%. Aktis Oncology has a consensus price target of $35.63, indicating a potential upside of 80.65%. Given Aktis Oncology's higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Aktis Oncology's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Aktis Oncology	N/A	N/A	N/A

Aktis Oncology has lower revenue, but higher earnings than Relay Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.35M	381.75	-$276.48M	-$1.57	N/A
Aktis Oncology	$6.50M	163.07	-$63.73M	-$0.82	N/A

Summary

Relay Therapeutics beats Aktis Oncology on 9 of the 15 factors compared between the two stocks.

Get Aktis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTS vs. The Competition

Export

Metric	Aktis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.19B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-24.05	13.88	274.09	25.69
Price / Sales	163.07	1,353.16	642.55	79.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-6.82	15.40	10.47	6.32
Net Income	-$63.73M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-13.74%	-1.74%	-0.68%	0.17%
1 Month Performance	-24.10%	-6.20%	-3.18%	-3.27%
1 Year Performance	N/A	30.64%	15.12%	5.58%

Aktis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTS Aktis Oncology	2.9972 of 5 stars	$19.72 -10.8%	$35.63 +80.7%	N/A	$1.19B	$6.50M	N/A	79
EWTX Edgewise Therapeutics	3.3918 of 5 stars	$44.62 +0.5%	$50.33 +12.8%	+172.0%	$4.85B	N/A	N/A	127	Positive News Analyst Forecast
ACAD ACADIA Pharmaceuticals	4.3703 of 5 stars	$27.52 -1.1%	$34.36 +24.9%	+7.8%	$4.74B	$1.14B	12.40	798	Positive News Analyst Forecast
PBLS Parabilis Medicines	3.3833 of 5 stars	$36.16 -2.0%	$41.67 +15.2%	N/A	$4.47B	N/A	N/A	145	Positive News
IOVA Iovance Biotherapeutics	1.7139 of 5 stars	$9.26 +7.7%	$8.89 -4.0%	+392.3%	$4.19B	$324.97M	N/A	975	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTS) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aktis Oncology (AKTS) Competitors

AKTS vs. EWTX, ACAD, PBLS, IOVA, and RLAY

How does Aktis Oncology compare to Edgewise Therapeutics?

Summary

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Summary

How does Aktis Oncology compare to Parabilis Medicines?

Summary

How does Aktis Oncology compare to Iovance Biotherapeutics?

Summary

How does Aktis Oncology compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aktis Oncology (AKTS) Competitors

AKTS vs. EWTX, ACAD, PBLS, IOVA, and RLAY

How does Aktis Oncology compare to Edgewise Therapeutics?

Do insiders and institutionals hold more shares of AKTS or EWTX?

Do analysts recommend AKTS or EWTX?

Does the media refer more to AKTS or EWTX?

Which has preferable valuation and earnings, AKTS or EWTX?

Is AKTS or EWTX more profitable?

Summary

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Does the media favor AKTS or ACAD?

Which has stronger earnings and valuation, AKTS or ACAD?

Is AKTS or ACAD more profitable?

Do analysts prefer AKTS or ACAD?

Do insiders & institutionals hold more shares of AKTS or ACAD?

Summary

How does Aktis Oncology compare to Parabilis Medicines?

Does the media favor AKTS or PBLS?

Do analysts prefer AKTS or PBLS?

Is AKTS or PBLS more profitable?

Do institutionals and insiders hold more shares of AKTS or PBLS?

Which has better valuation and earnings, AKTS or PBLS?

Summary

How does Aktis Oncology compare to Iovance Biotherapeutics?

Do insiders and institutionals hold more shares of AKTS or IOVA?

Which has preferable earnings & valuation, AKTS or IOVA?

Do analysts recommend AKTS or IOVA?

Does the media refer more to AKTS or IOVA?

Is AKTS or IOVA more profitable?

Summary

How does Aktis Oncology compare to Relay Therapeutics?

Does the media prefer RLAY or AKTS?

Do insiders and institutionals have more ownership in RLAY or AKTS?

Do analysts rate RLAY or AKTS?

Is RLAY or AKTS more profitable?

Which has preferable valuation and earnings, RLAY or AKTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools